Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Study of SRP-4053 in DMD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with DMD, genotypically confirmed.~* Intact right and left biceps muscles or an alternative upper arm muscle group.~* Stable pulmonary and cardiac function.~* Minimum performance on 6MWT, North Star Ambulatory Assessment, and rise (Gowers) test as specified in the study protocol.~* On a stable dose of corticosteroids for at least 6 months.~Exclusion Criteria:~* Previous treatment with the experimental agents BMN-195 (SMT C1100) or PRO053.~* Current or previous treatment with any other experimental treatments within 12 weeks prior to study entry.~* Major surgery within the last 3 months.~* Presence of other clinically significant illness.~* Major change in physical therapy regime within the last 3 months.~Other inclusion and exclusion criteria may apply.

- Gender: MALE
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: SRP-4053 (Type: EXPERIMENTAL): Patients will receive SRP-4053 (golodirsen) intravenous (IV) infusions, weekly, at escalating dose levels as follows: Weeks 1-2, 4 mg/kg/week; Weeks 3-4, 10 mg/kg/week; Weeks 5-6, 20 mg/kg/week; Weeks 7-12, 30 mg/kg/week. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
- Part 1: Placebo (Type: PLACEBO_COMPARATOR): Patients will receive SRP-4053 placebo-matching IV infusions, weekly, for 12 weeks. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
- Part 2: SRP-4053 (Type: EXPERIMENTAL): All eligible patients from Part 1, as well as new patients, will receive SRP-4053 (golodirsen) 30 mg/kg/week IV infusions, weekly, for up to 168 weeks.
- Part 2: Untreated Group (Type: NO_INTERVENTION): Patients with DMD who have a genotypically confirmed deletion of exon(s) not amenable to treatment by exon 53 skipping, but who otherwise meet the same eligibility criteria as treated patients newly recruited to Part 2, will undergo the same study assessments as treated Patients (except for pharmacokinetic \[PK\] sampling and muscle biopsies), but at a reduced schedule through Week 144. The untreated patients are not considered as control group.

Based on this trial design, predict the completion outcome and termination type (if applicable).